ICICI Securities has maintained a Buy rating on Suzlon Energy, retaining an unchanged target price of Rs 65, implying 35% upside from the current market price of Rs 48.
News in Focus


ICICI Securities has reiterated a Buy rating on Tata Power Company, maintaining a target price of Rs 485, implying 31% upside from the current market price of Rs 371.

ICICI Securities has maintained a Buy rating on Coforge Limited, setting a target price of Rs 1,950, implying a 17% upside from the current market price of Rs 1,669.

ICICI Securities has maintained a Buy rating on Bharat Electronics, setting a target price of Rs 530, implying a 35% upside from the current market price of Rs 394.

Axis Securities has maintained a Buy rating on NTPC, though it has trimmed the target price slightly to Rs 420 from Rs 430, implying a 20% upside from the current market price of Rs 350.

ICICI Securities has maintained a Buy rating on Steel Authority of India, setting a target price of Rs 225, implying a 36% upside from the current market price of Rs 165.
Main Regional Stories

Axis Securities has maintained its Buy rating on Bank of Baroda, though it has trimmed the target price to Rs 290 from Rs 315, implying an 18% upside from the current market price of Rs 246.6.

Axis Securities has reiterated a Buy rating on Greenply Industries Limited, raising its target price to Rs 355 from Rs 340, implying a 19% upside from the current market price of Rs 298.

Axis Securities has reiterated a Buy rating on SBI Life Insurance Limited, setting a target price of Rs 2,350, implying a 27% upside from the current market price of Rs 1,859.
New Delhi: Industry dean Ratan Tata advised that nonattendance of strong uni
New Delhi: Punjab National Bank (PNB) increased its fixed de
In early trading (10:02 am), Advanta India is quoting at Rs 856, up Rs 65.85, or 8.33%. It is swapping with volume of 7,271 shares.
Hyderabad: Cipla Ltd will produce the primary three-in-one cocktail anti-AIDS medicine used for children. This accompanies the USFDA clearing a combining quantity of Boehringer Ingelheim’s Viramune, GlaxoSmithKline’s Epivir (or lamivudine) and Bristol-Myers Squibb’s Zerit (or stavudine), which are anti-retrovirals or drugs that fight back AIDS.









